Menu
Menu
We are thrilled to be the inaugural World Companion Diagnostics & Liquid Biopsy Summit Japan. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
SOPHiA GENETICS is pleased to announce its participation in the upcoming HGSA 2025 Congress, taking place in Sydney, Australia. As a leader in data-driven medicine, we look forward to engaging with the genetics and healthcare community at this prominent event.
We invite all attendees to visit us at Booth #5 to discover the latest innovations in our New Generation SOPHiA DDM™ Platform. Our showcase will highlight significant advancements in exome sequencing, as well as our cutting-edge oncology solutions, including MSK-ACCESS® and MSK-IMPACT®, both powered by SOPHiA DDM™.
Join us to learn how SOPHiA GENETICS is advancing precision medicine through robust, multimodal, and globally applicable solutions.
Exciting news! We are thrilled to welcome Amrita Hospital to our network. Based in Faridabad, India, Amrita Hospital is recognized as one of the premier healthcare institutions. The hospital improves the well-being of the local community through initiatives aimed at providing outstanding and affordable medical care in the spirit of compassion to all.
The hospital will leverage the SOPHiA DDM™ platform to further its work with rare disorders and cancers, adding exome, solid tumor, and blood cancer applications. They will be able to conduct this testing in-house, allowing for faster turnaround times for our clinicians and researchers.
Dr. Moushumi Suryavanshi, Head of Molecular Biology at Amrita Hospital, said, “As we continue to innovate and search for the best tools to bring the highest level of care for our patients, it is imperative that we offer advanced Next Generation Sequencing testing for our practices.
By adding the capabilities of SOPHiA DDM™, we will be able to find answers to complex health problems faster by keeping our samples in-house. In addition, by joining the SOPHiA GENETICS network, we will also have the opportunity to learn from a global community and be able to contribute insights found from Indian genomic data to the larger global community.”
“It is our mission to democratize data-driven medicine and bring the power of world-class technology and global insights to healthcare institutions worldwide, so we can elevate the level care for all patients. We are honored to work with Amrita Hospital to advance the field of precision medicine for their patients,” added Ricardo Ramos Mendonca Filho, PhD., Managing Director, LAPAC, SOPHiA GENETICS.
Learn more about our SOPHiA DDM™ platform.
Join us at ESMO Asia 2025! Learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform by leveraging our unique AI-powered expertise and comprehensive product offering. Discover how we uncover insights from complex oncology data, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines.
We are excited to announce our presence at the World Companion Diagnostics & Liquid Biopsy Summit APAC. Meet our BioPharma team to learn more about our liquid biopsy portfolio and how it supports BioPharma companies to address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are around, don’t miss our Plenary talk, to discover how SOPHiA GENETICS is empowering Pharma companies to advance precision medicine with next-generation genomics solutions, enhancing worldwide patient access to innovative therapies
“Innovative Ways to Democratize Precision Medicine Testing”
Nicholas Tan, Managing Director APAC, SOPHiA GENETICS
If you are around, don't miss our Plenary talk, on November 12th from 12.00 to 12.30 pm, to discover how SOPHiA GENETICS is empowering Pharma companies to advance precision medicine with next-generation genomics solutions, enhancing worldwide patient access to innovative therapies.
We’re thrilled to be back at International Congress of Pathology and Laboratory Medicine (ICPALM 2025)
Join SOPHiA GENETICS at Booth S26 as we showcase our latest breakthroughs in data-driven medicine. Discover how our advanced solutions are transforming clinical insights across Liquid Biopsy, Solid Tumors, Hematologic Malignancies, and more.
We look forward to connecting with you in person in Malaysia!
Abu Dhabi, United Arab Emirates; June 3, 2025: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS (Nasdaq: SOPH) to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers.
As part of the collaboration, M42 will integrate SOPHiA GENETICS’ MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE.
The new testing program will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population.
Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care."
Sameh El Fangary, Cluster President GCC, AstraZeneca, shared," At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.”
Ross Muken, President of SOPHiA GENETICS, said: "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalize care, monitor disease in real-time, and ultimately improve outcomes for patients across the region."
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.
Join SOPHiA GENETICS at Pathology Update 2025 in Australia!
We are thrilled to announce our participation in the Pathology Update 2025, organized by the Royal College of Pathologists of Australasia (RCPA), for the very first time! This prestigious event will take place in Australia, showcasing the theme: 'Excellence in Diagnosis.'
Visit us at Booth #30 to discover how SOPHiA GENETICS is revolutionising the field of precision medicine. As clinicians and pathologists work tirelessly to achieve more accurate diagnoses and improve patient outcomes, we are here to support these efforts with our innovative, data-driven solutions.
Register to Pathology Update 2025 through here
We are thrilled to announce our participation in the ESMO Asia Congress 2024!
Join the SOPHiA GENETICS team at booth #E406 and explore how we are driving groundbreaking innovations in cancer research and treatment.
From our collaboration with Memorial Sloan Kettering cancer Center to decentralize MSK-ACCESS and MSK-IMPACT, to our launch of SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution, we are committed to supporting clinical researchers with variant detection and analysis, biomarker discovery, and therapy selection.
We look forward to connecting with you at ESMO Asia 2024!
SOPHiA GENETICS™ is excited to be for the first time part of the BioJapan Congress. You will have the chance to chat with our team at booth to discuss our solutions and our universal SOPHiA DDM™ Platform.
Asia‘s Premier Hybrid Partnering Event
Oct 9 Wed - 11 Fri. 2024| PACIFICO Yokohama
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.